GB2541483B - Antimicrobial peptide formulations - Google Patents
Antimicrobial peptide formulationsInfo
- Publication number
- GB2541483B GB2541483B GB1604893.6A GB201604893A GB2541483B GB 2541483 B GB2541483 B GB 2541483B GB 201604893 A GB201604893 A GB 201604893A GB 2541483 B GB2541483 B GB 2541483B
- Authority
- GB
- United Kingdom
- Prior art keywords
- antimicrobial peptide
- peptide formulations
- formulations
- antimicrobial
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/19—Dichroism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/21—Polarisation-affecting properties
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1505393.7A GB201505393D0 (en) | 2015-03-30 | 2015-03-30 | Antimicrobal peptide formulations |
Publications (3)
Publication Number | Publication Date |
---|---|
GB201604893D0 GB201604893D0 (en) | 2016-05-04 |
GB2541483A GB2541483A (en) | 2017-02-22 |
GB2541483B true GB2541483B (en) | 2019-04-17 |
Family
ID=53178319
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1505393.7A Ceased GB201505393D0 (en) | 2015-03-30 | 2015-03-30 | Antimicrobal peptide formulations |
GB1604893.6A Active GB2541483B (en) | 2015-03-30 | 2016-03-23 | Antimicrobial peptide formulations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1505393.7A Ceased GB201505393D0 (en) | 2015-03-30 | 2015-03-30 | Antimicrobal peptide formulations |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3277261A1 (en) |
GB (2) | GB201505393D0 (en) |
WO (1) | WO2016156772A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113302347A (en) | 2018-11-19 | 2021-08-24 | 奥克泰特医疗公司 | Devices, systems, and methods for administering therapeutic solutions to a treatment site |
CN113318054A (en) * | 2021-05-10 | 2021-08-31 | 上海高庄生物科技有限公司 | Cosmetic antiseptic composition and preparation method thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060162A2 (en) * | 2000-02-15 | 2001-08-23 | Ohio University | Cationic, amphipathic beta-sheet peptides and uses thereof |
WO2005090385A2 (en) * | 2004-03-18 | 2005-09-29 | Ansata Therapeutics, Inc. | Compositions having antimicrobial activity and uses thereof |
WO2006127715A1 (en) * | 2005-05-23 | 2006-11-30 | The Board Of Trustees Of The Leland Stanford Junior University | Antimicrobial peptides |
WO2006128289A1 (en) * | 2005-06-02 | 2006-12-07 | University Of Manitoba | Use of brevinin-2r in the treatment of cancer |
WO2008059011A1 (en) * | 2006-11-15 | 2008-05-22 | Scil Proteins Gmbh | Artificial binding proteins based on a modified alpha helical region of ubiquitin |
WO2008104777A2 (en) * | 2007-03-01 | 2008-09-04 | The University Of Bristol | Peptide |
US8530409B1 (en) * | 2012-06-12 | 2013-09-10 | Dipexium Pharmaceuticals LLC | Stable pexiganan formulation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4942084B2 (en) * | 2005-11-24 | 2012-05-30 | 学校法人順天堂 | Apoptosis inhibitor |
CN102091319B (en) * | 2011-01-14 | 2012-11-07 | 哈尔滨工业大学 | Use of toad peptide antibiotic for preparing medicaments for treating herpes zoster |
-
2015
- 2015-03-30 GB GBGB1505393.7A patent/GB201505393D0/en not_active Ceased
-
2016
- 2016-03-22 EP EP16712396.7A patent/EP3277261A1/en not_active Withdrawn
- 2016-03-22 WO PCT/GB2016/000058 patent/WO2016156772A1/en active Application Filing
- 2016-03-23 GB GB1604893.6A patent/GB2541483B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060162A2 (en) * | 2000-02-15 | 2001-08-23 | Ohio University | Cationic, amphipathic beta-sheet peptides and uses thereof |
WO2005090385A2 (en) * | 2004-03-18 | 2005-09-29 | Ansata Therapeutics, Inc. | Compositions having antimicrobial activity and uses thereof |
WO2006127715A1 (en) * | 2005-05-23 | 2006-11-30 | The Board Of Trustees Of The Leland Stanford Junior University | Antimicrobial peptides |
WO2006128289A1 (en) * | 2005-06-02 | 2006-12-07 | University Of Manitoba | Use of brevinin-2r in the treatment of cancer |
WO2008059011A1 (en) * | 2006-11-15 | 2008-05-22 | Scil Proteins Gmbh | Artificial binding proteins based on a modified alpha helical region of ubiquitin |
WO2008104777A2 (en) * | 2007-03-01 | 2008-09-04 | The University Of Bristol | Peptide |
US8530409B1 (en) * | 2012-06-12 | 2013-09-10 | Dipexium Pharmaceuticals LLC | Stable pexiganan formulation |
Non-Patent Citations (1)
Title |
---|
Antimicrobial Agents and Chemotherapy, Vol. 60 No. 4, April 2016, ULAETO D. et al, "Destabilisation of alpha-helical structure in solution improves bactericidal activity of antimicrobial peptides: Opposite effects on bacterial and viral targets" * |
Also Published As
Publication number | Publication date |
---|---|
EP3277261A1 (en) | 2018-02-07 |
GB201505393D0 (en) | 2015-05-13 |
GB2541483A (en) | 2017-02-22 |
GB201604893D0 (en) | 2016-05-04 |
WO2016156772A1 (en) | 2016-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL289250A (en) | Stabilized anti-microbial peptides | |
IL273541A (en) | Formulations | |
IL268697A (en) | Formulations | |
GB2573068B (en) | Antimicrobial Compositions | |
IL269630A (en) | Niraparib formulations | |
IL269621A (en) | Niraparib formulations | |
IL273282A (en) | Niraparib formulations | |
HK1254343A1 (en) | Pharmaceutical formulations | |
HK1258803A1 (en) | Lisinopril formulations | |
PL3253232T3 (en) | Antimicrobial compositions | |
HK1254980A1 (en) | Blended formulations | |
IL254794A0 (en) | Pharmaceutical formulations | |
HK1257745A1 (en) | Peptide composition | |
EP3197479A4 (en) | Antimicrobial peptides | |
GB2528521B (en) | Novel antimicrobial peptides | |
GB201405891D0 (en) | Modified antimicrobial peptides | |
GB2541483B (en) | Antimicrobial peptide formulations | |
EP3310363A4 (en) | Antimicrobial formulations | |
GB201620963D0 (en) | Antimicrobial peptides | |
IL254075B (en) | Durable pest-repelling formulations | |
GB201714461D0 (en) | Formulations | |
GB201621277D0 (en) | Formulations | |
GB201618110D0 (en) | Formulations | |
GB201616366D0 (en) | Formulations | |
GB201615754D0 (en) | Formulations |